Despite the extensive preclinical evidence supporting the anti-leukemic effects of natural compounds against BCR-ABL, human clinical trials in CML remain remarkably scarce. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.